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Abstract
Deposition of crystallized monosodium urate (MSU) in joints as a result of hyperuricemia is
a central risk factor for gout. However other factors must exist that control the progression
from hyperuricaemia to gout. A previous genetic association study has implicated the toll-
like receptor 4 (TLR4) which activates the NLRP3 inflammasome via the nuclear factor-κB
signaling pathway upon stimulation by MSU crystals. The T-allele of single nucleotide poly-
morphism rs2149356 in TLR4 is a risk factor associated with gout in a Chinese study. Our
aim was to replicate this observation in participants of European and New Zealand Polyne-
sian (Māori and Pacific) ancestry. A total of 2250 clinically-ascertained prevalent gout cases
and 13925 controls were used. Non-clinically-ascertained incident gout cases and controls
from the Health Professional Follow-up (HPFS) and Nurses Health Studies (NHS) were
also used. Genotypes were derived from genome-wide genotype data or directly obtained
using Taqman. Logistic regression analysis was done including age, sex, diuretic exposure
and ancestry as covariates as appropriate. The T-allele increased the risk of gout in the clin-
ically-ascertained European samples (OR = 1.12, P = 0.012) and decreased the risk of gout
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in Polynesians (OR = 0.80, P = 0.011). There was no evidence for association in the HPFS
or NHS sample sets. In conclusion TLR4 SNP rs2143956 associates with gout risk in preva-
lent clinically-ascertained gout in Europeans, in a direction consistent with previously pub-
lished results in Han Chinese. However, with an opposite direction of association in
Polynesians and no evidence for association in a non-clinically-ascertained incident gout
cohort this variant should be analysed in other international gout genetic data sets to deter-
mine if there is genuine evidence for association.
Introduction
Deposition of crystallized monosodium urate (MSU) in joints as a result of hyperuricemia is a
central risk factor for gout. Genome-wide association studies of serum urate have confirmed
uric acid transporters SLC2A9 and ABCG2 as important loci, that are also associated with
gout, with weaker effects from other uric acid transporters [1–3]. Given that many individuals
with hyperuricaemia do not develop gout, other factors must exist controlling the progression
from hyperuricaemia to gout [4]. However, very little is known about the genetic basis of the
progression from hyperuricaemia to MSU crystal deposition to symptomatic gout [5]. The
auto-inflammatory nature of gout involves the activation of the innate immune response by
MSU crystals. A central pathway is primability and actual activation of the NLRP3 inflamma-
some and subsequent release of mature interleukin-1β [6, 7]. An important question is whether
or not genetic regulation of this pathway is a risk factor for gout.
Toll-like receptors (TLRs) are transmembrane pattern recognition receptors expressed by
innate immune cells that trigger an innate immune response by controlling distinct signaling
pathways [8]. In addition to microbial ligands, these receptors also trigger innate immune
response against endogenous ligands including MSU crystals [9]. To date ten functional
human TLRs (TLR1-10) have been identified [10] of which TLR4 is a prominent member and
which has been associated with a number of auto-inflammatory conditions [11]. This receptor
activates the NLRP3 inflammasome via the nuclear factor-κB signaling pathway. A TLR4 single
nucleotide polymorphism (SNP; rs2149356) has been reported to be associated with gout in a
Han Chinese sample set [12], where the TT-genotype was associated with an increased risk of
gout (OR = 1.96 [95% CI 1.40–2.74]). The same genotype was associated with increased TLR4
mRNA expression and increased IL1β expression [12]. Our aim was to replicate the genetic
association of rs2149356 with gout in individuals of European and New Zealand Polynesian
ancestry.
Subjects and Methods
Subjects
Demographic and clinical data are presented in Table 1. All gout cases were clinically ascer-
tained according to the 1977 American Rheumatism Association (ARA) classification criteria
[13]. European cases (n = 1614) were recruited from New Zealand (n = 647), by the Eurogout
consortium within the European Crystal Network (n = 779) [14] and by the Arthritis Geno-
mics Recruitment Initiative in Australasia (AGRIA; n = 188). These cases were 84.1% male
with average age of 63.0 (20–97) years. European non-gouty controls (n = 13005), after
exclusion criteria applied as described below, were recruited from NZ (n = 875) and sourced
from the Atherosclerosis Risk in Communities (ARIC; n = 8781) and Framingham Heart
The TLR4 Gene and Gout
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(FHS; n = 3349 Generation 3 only) studies. The controls were 46.5% male with average age of
50.2 (17–95) years. There were 636 New Zealand Māori and Pacific Island (Polynesian) cases
(87.5% male with average age of 49.9 (17–100) years) and 920 controls (46.7% male with aver-
age age of 41.1 (17–85) years). Individuals who ever self-reported as having gout or taking
urate-lowering medication were excluded from the ARIC and FHS sample sets. The New Zea-
land Multi-Region Ethics Committee (MEC/105/10/130) and these institutional committees in
Europe and Australia granted ethical approval: Research and Ethics Committee, Repatriation
General Hospital, South Australia (32/08); Research Ethics Committee, University of New
South Wales; Ethikkommission, Technische Universität Dresden (EK 8012012); South East
Scotland Research Ethics Committee (04/S1102/41); Commission Cantonale (VD) D'éthique
de la Recherche sur l'être Humain, Université de Lausanne; Commissie Mensgebonden Onder-
zoek regio Arnhem—Nijmegen; Partners Health Care System Institutional Review Board. All
subjects gave written informed consent. The Database of Genotype and Phenotype (www.ncbi.
nlm.nih.gov/gap) approval number was #834 for accessing data from the ARIC and FHS
studies.
A separate data set, previously described in ref [15], of European Caucasian individuals was
investigated consisting of 726 incident male cases and 3445 controls from the Health Profes-
sionals Follow-up Study (HPFS) and 351 incident female cases and 6317 controls from the
Nurses Health Study (NHS) (Table 1). All cases were ascertained according to 1977 ARA classi-
fication criteria [13] using a self-administered gout questionnaire as previously described [16].
As summarised in ref [15] evaluation of medical records by two board-certified rheumatolo-
gists in a random audit set of 50 HPFS men demonstrated 94% (47/50) concordance of the
diagnosis of gout between the self-administered questionnaire and the review of medical rec-
ords and 91% (51/56) concordance in an audit sample of 56 NHS women.
Genotyping
Taqman genotyping for rs2149356 was performed for the sample sets excepting ARIC, FHS,
HPFS and NHS using a Lightcycler 480 Real-Time Polymerase Chain Reaction System (Roche
Applied Science, Indianapolis, USA) in 384-well plates. The FHS cohort had been genotyped
by the Affymetrix SNP 5 platform and a custom-designed gene-centric 50K SNP platform and
Table 1. Demographic and clinical data of participants.
European NZ Polynesian HPFS NHS
Control Gout Control Gout Control Gout Control Gout
Number 13005 1614 920 636 3445 726 6317 351
Male (%) 6049 (46.52) 1332 (84.14) 419 (45.89) 546 (87.50) 3445 (100) 726 (100) 00 (0.00) 00 (0.00)
Age 50.23±10.08 62.95±13.24 41.12±14.45 49.88±13.18 62.02±8.52** 61.73±9.60** 67.99±6.70** 64.95±9.85**
BMI 26.82±5.00
(12491)*
30.04±6.60
(1323)
32.67±7.26
(813)
35.79±7.69
(570)
25.84±3.34** 27.20±3.73** 26.31±5.15** 30.16±6.34**
Serum Urate
(mmol/L)
0.336±0.087
(12483)
0.399±0.136
(1118)
0.373±0.088
(680)
0.436±0.119
(484)
- - - -
Gout Duration
(Years)
_ 15.19±12.56
(1289)
_ 13.21±11.09
(548)
_ Incident
Cases
_ Incident
Cases
All values aside from sex are expressed as mean ± SD.
* For BMI, SU and gout duration, the ﬁgure inside the brackets represents the number of subjects with available data.
** Obtained at the time of gout onset among cases and at the mid-point time of cohort follow-up among controls.
doi:10.1371/journal.pone.0147939.t001
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rs2149356 genotype was imputed using MACH1 v1.0.15 with the HapMap CEU sample set as
reference haplotypes. In the ARIC sample set rs2149356 had been genotyped on the Affymetrix
SNP 6 platform. The HPFS and NHS sample sets were genotyped using the Illumina Infinium
OmniExpress and genotypes were imputed using MACH (imputation quality Rsq = 0.989).
This resulted in N = 10807 non-missing genotype calls (1.5% missing). There was no evidence
for departure from Hardy Weinberg equilibrium in any of the sample sets presented in Tables
2 and 3 (PHWE>0.01).
Statistical analysis
All logistic regression analysis was done using Intercooled STATA software version 8.0 (Col-
lege Station, TX 77845, USA). Allelic and genotypic odds ratios for gout were calculated and all
analyses were adjusted by age and sex, with the Polynesian analysis additionally adjusted by an
estimate of Polynesian ancestry calculated as previously described in order to account for
admixture with other ancestral groups [17]. A threshold of P< 0.05 was used to declare nomi-
nal statistical significance.
Results
In European and Polynesian subjects, the T-allele of rs2149356 was associated with the risk of
gout when compared to controls unstratified by urate level, but in an opposing direction of
association (Table 2; OREuropean = 1.12, P = 0.012 and ORPolynesian = 0.80, P = 0.011). The TT-
genotype was also associated with risk of gout when compared to the GG genotype, again in an
opposing direction of association (Table 1; OREuropean = 1.32, P = 0.006 and ORPolynesian = 0.63,
P = 0.009). Rs2149356 was then tested for association with gout in the HPFS and NHS studies
(Table 3). There was no evidence for association in either the allelic or genotypic analyses in
either of the studies (P0.31).
Discussion
Here we attempted to replicate the previously reported association with gout of TLR4 variant
rs2149356 in Han Chinese in sample sets of European and Polynesian ancestry. In the NZ and
Europeans recruited from Europe the association was replicated but with opposing direction in
the Polynesian sample set. A similar opposing direction of association between European and
Polynesian is also evident at other urate- and gout-associated loci PRKAG2 and HLF [2]. Why
Table 2. Rs2149356 genotype and association with risk of gout in NZ and Europe sample sets using ARIC and FHS controls.
Gout All Controls Adjusted OR[95%CI]1 P
European
GG 716 (0.444) 6093 (0.469) 1 1
GT 700 (0.434) 5529 (0.425) 1.068 [0.940–1.214] 0.32
TT 198 (0.122) 1383 (0.106) 1.317 [1.082–1.605] 0.006
T 1096 (0.340) 8295 (0.319) 1.122 [1.025–1.227] 0.012
NZ Polynesian
GG 181 (0.285) 241 (0.262) 1 1
GT 317 (0.498) 437 (0.475) 0.950 [0.710–1.272] 0.73
TT 138 (0.217) 242 (0.263) 0.634 [0.450–0.895] 0.009
T 593 (0.466) 921 (0.501) 0.800 [0.674–0.949] 0.011
1 Adjusted by age, sex and (for Polynesian) STRUCTURE estimate of Polynesian ancestry [17].
doi:10.1371/journal.pone.0147939.t002
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this is the case is not resolved, discussed further below. The third sample set (HPFS and NHS)
provided no evidence to support association of rs2149356 with gout. Two characteristics of this
sample set would have reduced chances of detecting association, should genuine association
exist. First, only ~90% have clinically-ascertained gout [16]. Second, the sample set are incident
gout cases (with minimum age of male cases 40 years and female cases 30 years [16]). Prevalent
cases are excluded—these excluded cases would be expected to have an earlier age of onset and
a stronger heritable component. On balance we are unable to conclude that the TLR4 locus to
be the first replicated genetic risk factor in gout outside of those that influence gout risk via
modulation of serum urate levels. However, given the very strong prior functional candidacy of
TLR4, we do consider that our study provides evidence consistent with a causal role for TLR4
in gout.
Regarding the inconsistent direction of association with gout between Polynesian, and Han
Chinese and European, the simplest explanation is that rs2149356 is not the causal variant but
in linkage disequilibrium with the causal variant, with a Polynesian-specific ancestral recombi-
nation event distinguishing the Polynesian haplotypic background around rs2149356 from
European and Han Chinese, resulting in the other (G) allele of rs2149356 being on the Polyne-
sian risk haplotype. The Polynesian population could be important in trans-ancestral genetic
fine-mapping of the etiological variant in TLR4 with the variant expected to be in a genomic
segment with the same alleles associated with gout between Han Chinese, European and Poly-
nesian. Other possibilities are that this marker is subject to stratification effects that have not
been adequately controlled in the Polynesian sample set, that there are non-genetic interactors
(e.g. alcohol and sugar-sweetened beverage consumption [18–20]) that are unaccounted for
and that would generate inconsistent rs2149356main effects or that these are chance findings
given the modest level of significance.
SNP rs2149356 is a common genetic variant of weak effect (OR1.4). More than 70% of
genetic variants for common phenotypes identified by genome-wide association studies map to
regulatory regions of the genome [21]. While it is possible that less common non-synonymous
functional variants in TLR4, that have been associated with other auto-inflammatory condi-
tions [22, 23], may also associate with gout, it is likely that the effect of rs2149356 on the risk of
gout is via an influence on expression of TLR4, either the amount of TLR4 produced and/or
relative levels of isoforms. Direct evidence of this was supplied by Qing et al. [12] who associ-
ated the TT-genotype rs2149356 with increased levels of TLR4 mRNA in peripheral blood
mononuclear cells (PBMCs) and increased serum interleukin-1β levels in people with acute
Table 3. Rs2149356 genotype and association with risk of gout in the HPFS and NHS sample sets.
Genotype Total Gout Unadjusted RR[95% CI] P Adjusted RR1 [95% CI] P
HPFS N = 4171 N = 726
GG 1920 336 1.00 - 1.00 -
GT 1824 315 0.98 [0.84–1.14] 0.78 0.99 [0.84–1.15] 0.84
TT 427 75 1.03 [0.80–1.32] 0.83 1.05 [0.82–1.35] 0.70
T 2251 390 0.99 [0.85–1.14] 0.85 1.00 [0.86–1.15] 0.94
NHS N = 6668 N = 351
GG 3137 176 1.00 1.00 -
GT 2901 143 0.88 [0.70–1.10] 0.25 0.89 [0.71–1.11] 0.29
TT 630 32 0.93 [0.64–1.36] 0.71 0.97 [0.66–1.42] 0.87
T 3531 175 0.88 [0.72–1.09] 0.24 0.90 [0.73–1.11] 0.31
1 Adjusted by age and diuretic usage.
doi:10.1371/journal.pone.0147939.t003
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gout. Conversely the TT-genotype associated with reduced levels of TLR4 mRNA in PBMCs
from people with intercritical gout. These important findings are consistent with the increased
risk observed for the TT-genotype for gout. Understanding how the T-allele controls expres-
sion of TLR4 will be important for improved molecular understanding of the pathogenic role
of the TLR4-pathway in gout. Our data, with an opposing direction of association in Polyne-
sian, suggest that rs2149356 is not causal but in linkage disequilibrium (LD) with, and a marker
for, the causal variant. Rs2149356maps to intron 4 of TLR4 but is in strong LD with two SNPs
in the promoter of TLR4 (rs2737190, r2 = 0.92 in Europeans and 0.97 in Asians, ‘-2570’ [24];
rs1927914, r2 = 0.93 in Europeans and 0.97 in Asians, -2026’ [24]). The gout risk allele (T) of
rs2149356 would be present (co-inherited) on a haplotype with the minor allele of each of these
promoter SNPs. The minor allele (G) of rs2737190 is predicted to create a v-Myb transcription
factor binding site and the minor allele (G) of rs1927914 is predicted to remove Oct-1 and C/
EBP transcription factor binding sites [24]. When studied individually in vitro, the rs2737190
G allele had no effect, but the rs1927914 G allele significantly decreased basal expression from
the TLR4 promoter and increased response to challenge with a uropathogenic Escherichia coli
strain [24], which is consistent with the observed expression pattern from Qing et al. [12]. This
genetic variant is therefore a candidate functional etiological variant for gout.
In conclusion, TLR4 SNP rs2143956 is associated with gout risk in prevalent clinically-ascer-
tained gout in Europeans, in a direction consistent with previously published results in Han
Chinese [12]. However, with an opposite direction of association in Polynesians and no evi-
dence for association in a non-clinically-ascertained incident gout cohort this variant should
be analysed in other international gout genetic data sets.
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